B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

NCT03931421 | Unknown Phase 2

• 1 other identifier: lymphoma center Q004
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

It's a single arm, open label prospective study, in which the safety and efficacy of B Cell Maturation Antigen（BMCA）-targeted CAR-T thearpy are evaluated in refractory/relapsed multiple myeloma patients.

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (2)

• complete remission rate

  complete remission rate after treated by CAR-T therapy

  at the time point 3 months after CAR-T cell transfusion

• incidence and severity of adverse events

  any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure

  from the date of the start of treatment to 36 months after last patient's enrollment

Secondary Outcomes (3)

• progression free survival

  from the day of treatment to the date of first documented progression，up to 36 months after the last patient's enrollment

• overall survival

  from the day of treatment to the date of first documented progression，up to 36 months after the last patient's enrollment

• duration of the CAR-T cells in the patients

  from the date of re-transfusison to 36 months after last patient's enrollment

Study Arms (1)

experiment group

EXPERIMENTAL

In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.

Biological: CAR-T treatment

Interventions

CAR-T treatment BIOLOGICAL

a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.

experiment group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Age≥18，male or female;
• \. ECOG 0-3;
• \. Clearly diagnosed as multiple myeloma (MM) \[according to IMWG 2014 criteria\];
• \. Patients should have received 3 different regimens prior to enrollment (each regimen should last for at least one complete cycle, except for the case of disease progression);
• \. Previously received one PI and IMiD treatment;
• \. MM patients should fit one of the following: 1) disease progression; 2) relapsed after CR. The corresponding criteria is defined as follows: a, disease progression should satisfy at least 1 of the following: serum M protein ≥0.5g/dl, or urine M protein\>200mg/24h, or FLC increasement \>10mg/dl, or bone marrow plasma cell proportion \>10%, or with new bone disease/plasmacytoma/original focus increased by 50% or more, or hypercalcemia ( corrected serum calcium level \>11.5mg/dL(2.65mmol/L); b. relapse after CR, should satisfy one of the following: ①M protein in urine or blood; ②bone marrow plasma cell proportion≥5%; ③manifestation of disease progression, such as plasmacytoma, osteolytic lesions or hypercalcemia.
• \. Peripheral blood mononucleated cell separation should be at least 2 weeks from chemo/radiotherapy;
• \. Neutrophil count≥1000/ul, platelet count≥45000/ul, Hb\>60g/l;
• \. Cardiac, hepatic and renal function: Creatinin \<1.5 times of normal maximum；ALT/AST level \<2.5 times of the maximum of normal range; total bilirubin\<1.5 times of ULN；cardiac ejection fraction≥ 50%; no pericardial effusion within 6 weeks prior to enrollment;
• \. Being able to understand and willing to sign the written consent;
• \. Fertile patients should agree to take contraceptive measures during the process of this trial.

You may not qualify if:

• \. History of other tumors other than multiple myeloma, except for the following: malignant tumor after radical surgery, and have been inactive for ≥3 years prior to enrollment; skin cancer (not melanoma) after sufficient treatment, no evidence of disease at enrollment;
• \. History of the following treatment: received targeted therapy, epigenetic therapy or clinical trials, invasive operation within 14 days/5 half-time prior to enrollment. History of monoclonal antibody within 21 days prior to enrollment. History of cytotoxic medicine or proteasome treatment within 14 days prior to enrollment. History of immunomodulatory treatment within 7 days prior to enrollment;
• \. History of \>5mg/d systemic prednisone treatment (or other glucocorticoids of the equivalent dosage) within 2 weeks prior to peripheral mononucleated cell collection;
• \. With CNS involvement or clinical manifestation of meningeal myeloma;
• \. With active systemic infection;
• \. With active HBV infection or HCV infection, or history of type C hepatitis;
• \. With immunodeficiency, including HIV infection;
• \. With the following heart condition: NYHA level III or IV congestive heart failure; myocardial infarction or CABG within 6 months prior to enrollment; clinically meaningful ventricular arrythmia, or history of idiopathic syncope (not caused by vascular-vagal disorder or dehydration), history of non-ischemic myopathy;
• \. With active autoimmune disease;
• \. History of autologous stem cell transplantation within 6 weeks prior to enrollment;
• \. History of allogenic stem cell transplantation.

Sponsors & Collaborators

• First Affiliated Hospital of Zhejiang University: lead

Study Sites (1)

The first affiliated hospital of Zhejiang University

Hangzhou, Zhejiang, 310000, China

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Wenbin Qian, MD,PhD

CONTACT

(+86)13605801032; qianwenb@aliyun.com

Hui Liu, MD,PhD

CONTACT

(+86)13819198629

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Masking Details: It's an open-label trial.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: clinical professor

Model Details: In this trial, T cells were seperated from refractory/relapsed multiple myeloma patients and engineered into BMCA-targeted CAR-T cells, and then transfused back into the patients for the treatment of their multiple myeloma.

Study Record Dates

• First Submitted: April 25, 2019
• First Posted: April 30, 2019
• Study Start: July 31, 2019
• Primary Completion: November 30, 2022
• Study Completion: December 31, 2022
• Last Updated: June 4, 2019

Record last verified: 2019-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, CSR

Locations

CN (1)